Profound Medical Corp. PROF

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001628808

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $77.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data; fortress balance sheet not computable: distress
Inputs computable	5 of 14
Graded from	filings received through Mar 5, 2026 251 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$7.66 2026-11-10; market equity $280.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies. Our lead product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 64.3						
Gross profitability	14.7%	32.3%		70.3	365	2025-12-31
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(5.9%)	(6.6%)		58.3	800	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 30.6					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(3.44)	(0.35)	49.7	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	12.52x	2.95x	11.4	826	2025-12-31
Growth and financing, sleeve percentile 60.6					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	20.8%	2.5%	60.6	628	2026-03-05

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 55,224,000 USD; Altman Z is not used

What the price implies

at the 2026-11-10 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(4.4%)	(1.9%)	48
Distance from 52-week high	(11.2%)	(28.5%)	70
EBIT to enterprise value	(16.3%)	(1.6%)	27
Free cash flow yield	(13.6%)	(1.0%)	28
Book value to price	0.15	0.27	33
Sales to price	0.06	0.29	18
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(0.21)	(0.19)	48

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$33.3M
Operating cash flow, four quarters	-$31.5M
Months of runway	12.7
Days since last periodic filing	6 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$786,857

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$11.4M	2025-12-31	2026-03-05	10-K	26-024153
2	assets	us-gaap:Assets	$77.5M	2025-12-31	2026-03-05	10-K	26-024153
3	operating income	us-gaap:OperatingIncomeLoss	-$41.3M	2025-12-31	2026-03-05	10-K	26-024153
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$42.3M	2025-12-31	2026-03-05	10-K	26-024153
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$252,000	2025-12-31	2026-03-05	10-K	26-024153
6	total debt	us-gaap:LongTermDebt	$4.5M	2025-12-31	2026-03-05	10-K	26-024153
7	book equity	us-gaap:StockholdersEquity	$66.4M	2025-12-31	2026-03-05	10-K	26-024153
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$59.7M	2025-12-31	2026-03-05	10-K	26-024153
9	total debt	us-gaap:LongTermDebt	$4.7M	2024-12-31	2026-03-05	10-K	26-024153
10	book equity	us-gaap:StockholdersEquity	$60.4M	2024-12-31	2026-03-05	10-K	26-024153
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$54.9M	2024-12-31	2026-03-05	10-K	26-024153
12	net income	us-gaap:NetIncomeLoss	-$42.6M	2025-12-31	2026-03-05	10-K	26-024153
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.2M	2025-12-31	2026-03-05	10-K	26-024153
14	assets	us-gaap:Assets	$70.2M	2024-12-31	2026-03-05	10-K	26-024153
15	current assets	us-gaap:AssetsCurrent	$76.1M	2025-12-31	2026-03-05	10-K	26-024153
16	current liabilities	us-gaap:LiabilitiesCurrent	$6.1M	2025-12-31	2026-03-05	10-K	26-024153
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$287.7M	2025-12-31	2026-03-05	10-K	26-024153
18	liabilities	us-gaap:Liabilities	$11.0M	2025-12-31	2026-03-05	10-K	26-024153
19	depreciation amortization	us-gaap:Depreciation	$373,000	2025-12-31	2026-03-05	10-K	26-024153
20	revenue	us-gaap:Revenues	$16.1M	2025-12-31	2026-03-05	10-K	26-024153
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.7M	2024-12-31	2025-03-07	10-K	25-000300
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$176,000	2025-12-31	2026-03-05	10-K	26-024153
23	current assets	us-gaap:AssetsCurrent	$69.1M	2024-12-31	2026-03-05	10-K	26-024153
24	current liabilities	us-gaap:LiabilitiesCurrent	$6.6M	2024-12-31	2026-03-05	10-K	26-024153
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,293,640	2026-03-05	2026-03-05	10-K	26-024153
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	30,039,809	2025-03-07	2025-03-07	10-K	25-000300

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.